Prognostic Factors in Lung Cancer Treatment
Author Information
Author(s): Betticher D C, Hsu Schmitz S-F, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R A, Pless M, Habicht J, Roth A D, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris H-B
Primary Institution: Clinic of Medical Oncology, Hospital of Fribourg, Switzerland
Hypothesis
The aim was to investigate the efficacy of neoadjuvant docetaxel–cisplatin and identify prognostic factors for outcome in locally advanced stage IIIA (pN2) non-small-cell lung cancer patients.
Conclusion
Neoadjuvant docetaxel–cisplatin was effective and tolerable in stage IIIA pN2 NSCLC, with chemotherapy contributing significantly to outcomes.
Supporting Evidence
- 75 patients underwent surgery after chemotherapy.
- Median overall survival was 35 months for patients who underwent surgery.
- 36% of patients were alive and tumor-free at 3 years.
- Factors associated with better outcomes included complete tumor resection and chemotherapy activity.
Takeaway
This study looked at how well a specific chemotherapy worked for lung cancer patients and found that it helped many of them live longer.
Methodology
Patients received three cycles of docetaxel and cisplatin before surgery, and their outcomes were analyzed based on various prognostic factors.
Potential Biases
Potential biases may arise from the single-arm design and the lack of a control group.
Limitations
The study had a relatively small sample size and was limited to a specific patient population.
Participant Demographics
Patients were aged 18-75 years, with a mix of genders and performance statuses.
Statistical Information
P-Value
p=0.0002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website